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Abstract 
Previous tudies have shown that the pattern and degree of 3-(trifluoromethyl)-3-(m-[12sI]iodophenyl)diazirine ([125I]TID) photoincor- 
poration into the nicotinic acetylcholine receptor (nAChR) can be used as a sensitive measure of nAChR conformation. Upon 
desensitization by prolonged exposure to agonists, certain drugs and detergents, or reconstitution i to desensitizing lipids, the levels of 
[125I]TID incorporation i to the subunits of the nAChR are dramatically reduced. In this study, we characterized the effects of the snake 
venom proteins a-bungarotoxin and a-cobrotoxin, as well as the smaller antagonists tubocurarine and gallamine, on [125I]TID 
incorporation i to the subunits of both partially-purified nAChR in native lipids, or affinity-purified nAChR reconstituted into different 
combinations of lipids. Unlike all other compounds previously tested, a-bungarotoxin a d a-cobrotoxin reproducibly increased the level 
of [125I]TID incorporation i to all four subunits of nAChR reconstituted into dioleoylphosphatidylcholine, dioleoylphosphatidic acid and 
cholesterol. Gallamine had little or no effect on [125I]TID incorporation at any concentration tested (0.1 /xM-5 mM). Tubocurarine had 
no effect on [125I]TID incorporation at low concentrations, but at higher concentrations reduced the level of [a25I]TID labeling. The snake 
venom proteins may shift the population of nAChR, which exists as a mixture of resting state and desensitized conformations, entirely to 
the resting state. However, the binding of the snake venom toxins does not appear sufficient o induce the resting state conformation i
nAChR which have been desensitized by other means, such as solubilization in desensitizing detergents or reconstitution i desensitizing 
lipids. 
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1. Introduction 
The nicotinic acetylcholine receptor (nAChR) is the 
primary signal transducer at the neuromuscular junction. 
The nAChR is a multi-subunit, intrinsic membrane protein 
(reviews of the structural and biochemical aspects of 
nAChR function include [1-3]). Operationally, the nAChR 
can be thought to assume at least four conformational 
states; the resting, open, intermediate desensitized, and 
equilibrium desensitized states. Binding of the agonist 
Abbreviations: nAChR, nicotinic acetylcholine r ceptor; BgTx, a- 
bungarotoxin; [125I]TID, 3-(trifluoromethyl)-3-(m-[X251]iodophenyl) - 
diazirine; octylglucoside, n-octyl-/3-D-glucopyranoside; DOPC, dioleoyl- 
phosphatidylcholine; DOPA, dioleoylphosphatidic acid; SDS, sodium 
dodecylsulfate; PAGE, polyacrylamide g l electrophoresis. 
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acetylcholine causes the nAChR ion channel to open, 
allowing the depolarizing influx of cations through the 
muscle cell membrane. A number of agents block the 
action of agonists at the nAChR, both competitively and 
non-competitively. The competitive blockers can be arbi- 
trarily separated into two groups; snake venom toxins 
(--" 8000 Da proteins), and lower molecular weight com- 
pounds. The snake venom toxins, such as a-bungarotoxin 
and a-cobrotoxin, bind with high affinity (K  d less than 
nM) [4-7] to neuromuscular nAChR and competitively 
block agonist binding. The smaller antagonists, uch as the 
plant alkaloid d-tubocurarine (the active ingredient of cu- 
rare) or gallamine bind with weaker affinity to the nAChR 
[8-10]. Non-competitive blockers reduce agonist activity 
by inducing desensitization and/or  blocking ion flow 
through the protein, and not surprisingly their action ap- 
pears to be quite sensitive to the functional conformation 
of the nAChR [11]. However, in some (but not all) earlier 
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studies performed upon partially-purified nAChR, the snake 
venom toxins appeared relatively insensitive to the confor- 
mational state of the nAChR. 
We re-determined the effects of competitive antagonists 
on the conformation of the nAChR using the hydrophobic 
photoprobe, 3-(trifluoromethyl)-3-(m-[125 I]iodophenyl)- 
diazirine ([125I]TID). The pattern of [125I]TID incorpora- 
tion into the nAChR is dependent upon the functional 
conformation of the nAChR. All four subunits of resting 
state nAChR are labeled by [125I]TID, with enhanced 
labeling of the 7-subunit (ratio of label incorporation into 
the "y-subunit relative to the a-subunit > 2 [12]). Upon 
desensitization by prolonged exposure to agonist, label 
incorporation i to all four subunits is reduced [13,14], and 
the ratio of label incorporated into the "y-subunit relative to 
the a-subunit is approximately equal [12]. We have also 
shown that reconstitution i to certain lipids, or solubiliza- 
tion in some (but not all) detergents, had the same effect 
on nAChR [125I]TID-labeling as prolonged incubation with 
agonist, suggesting that agonists, and particular lipids and 
detergents, all induced the same final desensitized nAChR 
conformation [12]. Recently, Cohen and co-workers 
demonstrated that the conformationally-sensitive 
[125I]TID-incorporation site is within the portion of the 
nAChR thought to form the lining of the ion channel 
[15,16], in agreement with other studies which demonstrate 
that [125 I]TID binding and labeling is competitively blocked 
by certain non-competitive blockers [13,17,18]. 
In the studies reported here, we observed that, unlike all 
other reagents tested to date, the snake venom toxins 
a-bungarotoxin (BgTx; from Bungarus multicinctus) and 
a-cobrotoxin (from Naja naja kaouthia) increased the 
levels of [125I]TID incorporation (largely into the "y-sub- 
unit) of both affinity-purified nAChR reconstituted into 
defined lipids and enriched nAChR-containing membranes 
in native lipids. However, the smaller antagonists d-tubo- 
curarine and gallamine had no effect on [125I]TID incorpo- 
ration at low concentrations, while at higher concentrations 
d-tubocurarine reduced the levels of [125I]TID labeling. 
Our results suggest hat the snake venom toxins act to 
stabilize the resting state conformation of the nAChR, 
leading to increased [ 125 I]TID incorporation, while at higher 
concentrations d-tubocurarine may reduce [125I]TID incor- 
poration by inducing desensitization, or by competing with 
[125I]TID binding to the ion channel region of the nAChR 
directly. 
2. Experimental procedures 
2.1. Materials 
[125I]TID (8-10 Ci/mmol) and [125I]-a-bungarotoxin 
([125I]BgTx) (3000 Ci/mmol) were purchased from Amer- 
sham (Arlington Heights, IL). Egg lecithin (dioleoylphos- 
phatidylcholine; DOPC) and dioleoylphosphatidic acid 
(DOPA) were purchased from Avanti Polar Lipids (Pelham, 
AL). Cholesterol was purchased from Boehringer 
Mannheim (Indianapolis, IN). Carbamylcholine, gallamine 
triethiodide, d-tubocurarine chloride, a-bungarotoxin (from 
Bungarus multicinctus) and a-cobrotoxin (from Naja naja 
kaouthia) were purchased from Sigma (St. Louis, MO). 
Live Torpedo californica were purchased from Marinus 
(Long Beach, CA). 
2.2. Acetylcholine receptor purification and reconstitution 
Torpedo californica electric organs were collected, and 
both enriched nAChR membranes in native lipids [14,19], 
or affinity-purified nAChR reconstituted into either DOPC 
alone, or a mixture of DOPC/DOPA/cholesterol (molar 
ratio between the lipids of 3:1:1) [12,18], were prepared as 
described previously, nAChR reconstituted in 
DOPC/DOPA/cholesterol appears functional by a num- 
ber of criteria, while nAChR reconstituted in DOPC ap- 
pears to be essentially locked in the desensitized conforma- 
tion [12,20,21]. Small aliquots (-- 300 /xl) of the purified 
nAChR were stored in liquid N 2 at a protein concentration 
of 1.5 mg/ml until use, typically within 3 weeks of 
preparation. In these studies, five separate preparations of 
enriched nAChR membranes and four preparations of 
affinity-purified nAChR (three reconstituted into 
DOPC/DOPA/cholesterol and one reconstituted into 
DOPC alone) were tested. On the basis of [125I]BgTx 
binding [22], the enriched nAChR membranes averaged 
70% pure (5.23 ___ 0.38 nmol [125I]BgTx bound/mg pro- 
tein) while the affinity-purified nAChR were 100% pure 
(7.47 _ 0.34 nmol [125I]BgTx bound/mg protein). 
2.3. [125I]TID labelling 
The [125I]TID photolabeling experiments were per- 
formed largely as described in earlier studies [12,18]. 
Basically, in a final volume of 50/xl, nAChR (0.4/zM) in 
10 mM Mops, 100 mM NaC1, 0.1 mM EDTA, 0.2% 
NAN3, pH 7.5 was equilibrated for 30 min at room temper- 
ature in the absence or presence of 100-300 /zM car- 
bamylcholine, a-bungarotoxin or a-cobrotoxin (2-10 × 
molar excess over nAChR binding sites), or gallamine 
triethiodide or d-tubocurarine (0.1 /zM 5 mM) (see text for 
drug concentrations used in individual experiments). 
[125I]TID (1 /xCi) was then mixed with the nAChR/ligand 
solution by repeated pipeting (final ratio of 18 pmol 
AChR/80-100 pmol [125I]TID), and equilibrated for 10 
min. Photolabeling of the nAChR with [125I]TID was 
performed by exposing each reaction mixture to long- 
wavelength UV light (Ama x= 366 nm) at a distance of 3 
cm for 10 min (conditions which yield maximal label 
incorporation). In experiments where the effects of deter- 
gent on [125I]TID incorporation in the presence of toxins 
was tested, the nAChR was solubilized in octylglucoside 
(1%, w/v )  for 30 min at room temperature prior to 
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addition of toxin and photolabel. Photolabeling was termi- 
nated by removal of the reaction mixtures from the UV 
light, after which each mixture was reduced by the addi- 
tion of 6 ~1 of 2 mM dithiothreitol. 15 ~1 aliquots of each 
reaction mixture were then mixed with 15 ~1 of IEF 
sample buffer [23] and then equilibrated for 30 min at 
room temperature prior to SDS/PAGE analysis. 20 ~1 
aliquots of each reduced reaction mix were applied per gel 
lane. SDS/PAGE separation of the [ 1251]TID-labeled 
nAChR subunits was performed as described previously 
[12]. Autoradiograms were prepared using Kodak X-Omat 
RP film at - 70” C in the presence of a Cronex Lightning 
Plus intensifying screen. 
The extent of [ lz51]~1~ incorporation into the subunits 
of the nAChR was quantitated by cutting out the bands of 
interest and measuring the amount of [“‘I] present in each 
band using a Packard Cobra y counter. The concentration 
at which d-tubocurarine diminished [ lz5 I]TID incorpora- 
tion by 50% of its maximal effect (IC,,) was determined 
by fitting the dose-response data to the four parameter 
logistic equation as described [18]. 
3. Results 
These studies were prompted by earlier nAChR 
[‘251]TID-labeling experiments in which we used BgTx to 
block drug binding to the agonist binding site [18]. Unex- 
pectedly, in some instances, the amount of [1251]TID incor- 
porated into affinity-purified nAChR was significantly in- 
creased in the presence of BgTx. This observation was 
unexpected because in earlier studies performed both by 
ourselves [14] and others [13], BgTx had virtually no effect 
on [rz51]TID incorporation into enriched nAChR mem- 
branes. We therefore decided to re-determine the effects of 
antagonists on the patterns of [ 125 IITID into the subunits of 
the nAChR, to test whether antagonist binding altered 
nAChR conformation. 
First, we determined whether snake venom toxins such 
as BgTx enhanced [‘251]TID incorporation into both func- 
tionally-reconstituted affinity-purified nAChR and en- 
riched nAChR membranes. As shown in Fig. 1, BgTx 
binding caused increased [ 125~]~~~ labeling into both types 
of nAChR preparation, although the effect was more pro- 
nounced for functionally-reconstituted affinity-purified 
nAChR (Fig. lb) than for enriched nAChR membranes 
(Fig. la). The extent to which BgTx enhanced [125~]~~~ 
into affinity-purified nAChR varied somewhat (between 
30-80%) with different affinity preparations; in the prepa- 
ration shown in Fig. lb, BgTx increased [ 1251]TID incorpo- 
ration into the y-subunit by 40 + 11% (average and stan- 
dard deviation of six determinations). However, while 
enhanced [‘251]TID incorporation in the presence of snake 
venom toxins was always observed for affinity-purified 
nAChR reconstituted into DOPC/DOPA/cholesterol 
(three separate preparations tested), the effect was more 
--!Lc a 
-+-+-+ 
Pig. 1. Effects of antagonists on [lz5 IRID-labeling of different nAChR 
preparations. nAChR was pre-equilibrated for 30 min in the absence (-) 
or presence ( + 1 of saturating BgTx (5 X molar excess over binding sites) 
prior to equilibration with [ ‘251]TID for 10 min and subsequent photola- 
beling. Labeled nAChR subunits were then separated by SDS-PAGE. 
Shown is an autoradiogram of a, enriched nAChR in native lipids, b, 
affinity-purified nAChR reconstituted into DOPC/DOPA/cholesterol, 
and c, affinity-purified nAChR reconstituted into DOPC, labeled with 
[‘*‘I]TID in the presence or absence of BgTx. The positions of the 
nAChR subunits are indicated. The band beneath the p subunit is most 
likely a proteolytic product of the y subunit which is sometimes observed 
1131. 
variable for enriched nAChR membranes. Two enriched 
nAChR membranes preparations showed no change in 
[‘25~]TID incorporation in the presence of BgTx, two 
showed moderate but significant enhancement (= 15- 
25%) and in one preparation, BgTx binding increased 
[ 125 I]TID incorporation by = 50%. As described more 
fully in Section 4, we believe the variable effects of BgTx 
on nAChR conformation observed with different prepara- 
tions of nAChR, as detected by [i251]TID labeling, is 
determined by the pre-existing resting state/desensitized 
state ratio of each nAChR preparation. However, BgTx did 
not alter the level of [ 1251]TID incorporation into nAChR 
which was no longer able to shift between the resting and 
desensitized states. As shown Fig. lc, affinity-purified 
nAChR reconstituted into DOPC alone was labeled to 
about the same extent by [12’1]~1~ in both the presence 
and absence of BgTx (the slight enhancement of [125~]~~~ 
incorporation into nAChR reconstituted into DOPC by 
BgTx apparent in Fig. 1 was neither significant or repro- 
ducibly observed, averaged over six determinations). In 
earlier studies, both ourselves and others have shown that 
nAChR reconstituted solely into DOPC is not able to 
undergo the change in conformation between the resting 
and desensitized states, and in fact appears to be entirely in 
the desensitized conformation [12,21]. 
The observation that BgTx increased the extent of 
[ ‘251]TID incorporation into functional nAChR suggested 
to us that snake toxin venoms might be acting to shift a 
portion of the nAChR population from a desensitized state 
to the resting state conformation. However, the inability of 
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BgTx to enhance [a25I]TID labeling of nAChR reconsti- 
tuted into DOPC implied that snake venom toxins could 
not shift 'profoundly' desensitized nAChR to the resting 
state. To test this notion further, we determined the effect 
of BgTx on [125I]TID labeling of detergent-solubilized 
nAChR using the non-denaturing detergent octylglucoside, 
which appears on the basis of its effects on [125I]TID 
labeling to desensitize the nAChR [12]. As shown in Fig. 
2, solubilization in octylglucoside r duced [125I]TID incor- 
poration into enriched nAChR membranes to the same 
extent as incubation with desensitizing concentrations of 
the agonist carbamylcholine; compare the leftmost lane 
(-additives) with samples labeled in the presence of 
carbamylcholine (c) or octylglucoside (OG), while BgTx 
increased [125I]TID incorporation into membrane-bound 
nAChR; compare the sample labeled in the absence of 
additives ( - )  with that labeled in the presence of BgTx 
(TX). However, for octylglucoside-solubilized nAChR, 
BgTx did not induce the pattern of [12SI]TID labeling 
characteristic of resting state nAChR (increased labeling of 
all four subunits, with enhanced labeling of the y-subunit), 
as shown in the rightmost lane (TX/OG). The inability of 
BgTx to induce the resting state pattern of [125I]TID 
labeling for nAChR reconstituted in DOPC or solubilized 
in octylglucoside suggests that snake venom toxins can not 
shift nAChR from the equilibrium desensitized state back 
to the resting state. 
We also tested whether other antagonists influenced 
labeling of the nAChR by [125I]TID. As shown in Fig. 3, 
like BgTx, a-cobrotoxin (3 × molar excess over binding 
sites) increased the extent of [125I]TID incorporation into 
enriched nAChR membranes; compare the left most lane 
(-additives) with the rightmost lane (TX). However, the 
non-proteinaceous antagonists d-tubocurarine and gal- 
Tx 
c Tx OG OG 
8-  
Fig. 2. Effects of detergent and antagonists on nAChR conformation. 
[125I]TID-labeling was performed as described in the legend to Fig. 1. 
Detergent solubilization was performed as described in Experimental 
procedures. Shown is an autoradiogram of enriched nAChR membranes 
labeled with [125I]TID in the absence ( - )  or presence of 300 p.M 
carbamylcholine (c), saturating a-bungarotoxin (Tx; 7× molar excess 
over binding sites), 1% octylglucoside (OG) or both ot-bungarotoxin a d 
1% octylglucoside (Tx/OG). The positions of the nAChR subunits are 
indicated. 
y-  
O r ,  - -  
- c Tu  Ga Tx  
Fig. 3. Effects of antagonists on nAChR [125I]TID-labeling. [125I]TID 
labeling was performed as described in the legend to Fig. 1. Shown is an 
autoradiogram of enriched nAChR membranes [125I]TID-labeled in the 
absence ( - )  or presence of 300 /xM carbamylcholine (c), 10 /xM 
d-tubocurarine (Tu), 10 /xM gallamine (Ga), or saturating ot-cobrotoxin 
(Tx; 3 × molar excess over binding sites). The positions of the nAChR 
subunits are indicated. 
lamine (at 10 /~M) had essentially no effect on [125I]TID 
incorporation; compare the sample labeled in the absence 
of additives ( - )  with that labeled in the presence of 
d-tubocurarine (Tu) or gallamine (Ga). This suggests that 
the relatively large (-~ 8000 Da) snake venom toxins can 
stabilize the resting state conformation of the nAChR 
whereas the smaller antagonists can not. The concentra- 
tions of d-tubocurarine and gallamine used in the experi- 
ment depicted in Fig. 3 are well over the dissociation 
constant for the high affinity d-tubocurarine binding site 
and slightly above the dissociation constants for lower 
affinity d-tubocurarine and gallamine binding [8-10,24,25]. 
However, we tested the effects of d-tubocurarine and 
gallamine on nAChR [125I]TID labeling over a wide range 
of concentrations, to determine if these ligands could alter 
nAChR conformation at higher concentrations, in particu- 
lar as an earlier publication had shown that 100 tzM 
d-tubocurarine began to reduce [125I]TID incorporation 
significantly [13]. As shown in Fig. 4a, at relatively high 
concentrations, d-tubocurarine r duced [125I]TID incorpo- 
ration into enriched nAChR membranes to the same extent 
as carbamylcholine. The inhibition of [125I]TID incorpora- 
tion by high concentrations of d-tubocurarine could be due 
to d-tubocurarine induced desensitization, or direct compe- 
tition by d-tubocurarine for the [125I]TID binding site. The 
calculated IC50 for d-tubocurarine inhibition of [125I]TID 
incorporation into the nAChR y-subunit, determined from 
six experiments performed as in Fig. 4a, was 453 /~M. 
However, as shown in Fig. 4b, at concentrations a high as 
5 raM, gallamine had little effect on labeling of the 
nAChR by [125I]TID. This suggests that, even at high 
concentrations, gallamine did not desensitize enriched 
nAChR membranes, in agreement with earlier studies 
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demonstrating that gallamine functions as a pure, non-de- 
sensitizing antagonists. Finally, while the data shown in 
Fig. 4 were determined using enriched nAChR mem- 
branes, the results were the same using affinity-purified 
nAChR reconstituted into DOPC/DOPA/cholesterol. 
4. Discussion 
The primary observation of this publication is that 
snake venom toxin proteins uch as BgTx and a-cobroto- 
xin, but not the smaller antagonists d-tubocurarine and 
gallamine, increase the degree of [t25I]TID labeling of both 
enriched nAChR membranes and functionally reconstituted 
affinity-purified nAChR. The simplest mechanism to ex- 
plain this observation is that the snake venom toxins, but 
not other nAChR antagonists, shift the population of 
nAChR entirely to the resting state. As depicted in the 
reaction scheme below, modified from earlier studies based 
1 2 3 4 5 6 7 8 9 
a 
y-  
f t - -  
y-  
Ct - -  
Fig. 4. Effects of d-tubocurarine or gallamine on [125I]TID incorporation 
into the nAChR. [125I]TID-labeling was performed as described in the 
legend to Fig. 1. Shown are autoradiograms of enriched nAChR mem- 
branes labeled with [125I]TID in the absence (lane 1) or presence of 100 
/.~M carbamylcholine (lane 2) or d-tubocurarine (a) or gallamine (b) at 0.1 
/zM, 1 /zM, 25 k~M, 250 /~M, 750 btM, 1 M, and 5 mM (lanes 3-9). 
The positions of the nAChR subunits are indicated. 
on radioactive ion flux and other measurements [26-28], 
the population of nAChR exists in a ratio of resting/de- 
sensitized states even in the absence of agonists or other 
functional modulators. 
A A 
60-80% R----~-----~RA~--~ARA.,, \AR*A 
20-40% D I~----X D iA ~---~A D IA ~--- XA DeqA 
In this scheme, R is resting state or activatable nAChR, A 
is agonist, R* is open state nAChR, Di is intermediate 
desensitized nAChR and Deq is equilibrium desensitized 
nAChR (although not shown for reasons of clarity, agonist 
can bind to the un- and mono-liganded Di conformation of
the nAChR as well). The numbers to the left of the 
reaction scheme are the predicted proportions of Torpedo 
nAChR thought o pre-exist in the resting or desensitized 
states in the absence of ligands. Enriched nAChR mem- 
branes apparently are = 10-20% in the high-affinity (de- 
sensitized) conformation i  the absence of agonists [29-31], 
while functionally-reconstituted affinity-purified nAChR 
may vary between 20-40% in the pre-existing desensitized 
state [21]. Binding of snake venom toxins apparently shifts 
the population of nAChR entirely to the resting state 
conformation. This would result in increased [125I]TID 
incorporation i to its specific labeling site within the ion 
channel of the nAChR, which is labeled by [125I]TID 
predominantly in resting state, but not desensitized nAChR 
[17]. The magnitude of the enhancement in [lasI]TID in- 
corporation i  the presence of snake venom toxins agrees 
with this mechanism, and would explain why the effect 
was greater with affinity-purified nAChR than with en- 
riched nAChR membranes. The variability of the effect of 
snake venom toxins on [125I]TID incorporation between 
different preparations of nAChR also agrees with this 
mechanism, as different preparations of nAChR have been 
shown to vary in their pre-existing resting/desensitized 
state ratio [30,31]. 
Earlier workers have split on whether snake venom 
toxins bind preferentially to one or another functional 
state, or cause changes in nAChR conformation. While 
some early studies suggested that snake venom toxins did 
not stabilize the resting state [32], and that snake venom 
toxins bound with equal affinity and kinetics to both 
resting state and desensitized Torpedo nAChR [33,34], a 
number of other lines of research suggest that snake 
venom toxins do stabilize the resting state. Perhaps the 
best evidence is provided by the numerous tudies which 
show that snake venom toxins allosterically inhibit the 
binding of certain non-competitive blockers which are 
known to bind with higher affinity to desensitized nAChR 
[11,35-38], while in a more recent study, a-cobrotoxin 
was seen to block enhanced binding of ethidium to the 
NCB site by general anesthetics [39]. Further support for 
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the ability of snake venom toxins to stabilize the resting 
state conformation is found in studies of the opposing 
effects of agonists and snake venom toxins on the nAChR. 
For example, in studies of T. californica nAChR, BgTx 
enhanced quenching of the fluorescent probe pyrene sulfo- 
nyl azide while carbamylcholine inhibited quenching [40], 
BgTx binding caused increased calcium uptake while car- 
bamylcholine induced calcium release [41], BgTx dimin- 
ished [3H]ethidium labeling while carbamylcholine n- 
hanced label incorporation into all four subunits [42], and 
in our own earlier studies, BgTx retarded exchange of 
bound tritium while agonists either slightly accelerated 
exchange or had no effect [19]. The bulk of the earlier 
work, and our results reported here, are clearly most 
consistent with a model in which snake venom toxin 
binding stabilizes the resting state conformation of the 
nAChR, and the discrepant results between different stud- 
ies (including our earlier report of the effects of BgTx on 
nAChR [125I]TID labeling [14]), are probably due to varia- 
tion in the ratio between resting and desensitized nAChR 
pre-existent in different preparations of the protein. How- 
ever, since the snake venom toxins were not able to 
stabilize the resting state in nAChR preparations which 
were profoundly desensitized, by reconstitution i to DOPC 
or solubilization in desensitizing detergent, it appears that 
the desensitized form of the nAChR which makes up a 
fraction of the total nAChR population in the absence of 
ligands is the intermediate desensitized state (Di in the 
reaction scheme above) and that BgTx will not induce or 
stabilize the resting state in equilibrium desensitized 
nAChR. 
The effects of d-tubocurarine and gallamine on [mI ]T ID 
labeling of the nAChR are consistent with earlier studies. 
At high (mM) concentrations, d-tubocurarine reduced 
p25I]TID incorporation to the same extent as agonist-in- 
duced desensitization. However, the mechanism by which 
d-tubocurarine effected this reduction is not clear. In addi- 
tion to acting as a competitive inhibitor blocker of agonist 
binding [43], with Torpedo nAChR d-tubocurarine has 
been observed to induce desensitization i some [9,34] (but 
not all [44]) studies and both to activate or block non-com- 
petitively the nAChR ion channel in rat muscle nAChR 
[45,46] or Electrophorus electricus nAChR [47], respec- 
tively. In the studies reported here, the calculated IC50 for 
d-tubocurarine reduction of [12SI]TID incorporation was 
453/xM, which is in general much higher than the concen- 
tration of d-tubocurarine required to produce the effects 
reported in the earlier studies cited above. Therefore, 
d-tubocurarine reduction of [125I]TID incorporation might 
be due to induction of desensitization, or perhaps more 
likely, given the concentration dependence of the effect, by 
direct competition of d-tubocurarine for the specific 
[12s I]TID binding site in the non-competitive blocker bind- 
ing region in the nAChR channel. Gallamine, on the other 
hand, did not reproducibly diminish [125I]TID incorpora- 
tion even at high gallamine concentrations. In earlier stud- 
ies, gallamine did not appear to induce nAChR desensitiza- 
tion [44], but did act as a non-competitive blocker of frog 
muscle nAChR [48]. The failure of gallamine to diminish 
[125I]TID incorporation is in agreement with the earlier 
observation that gallamine did not desensitize the nAChR, 
and if gallamine does bind to the ion channel region of 
Torpedo californica nAChR, this binding apparently does 
not compete with [125I]TID binding to its high affinity site. 
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